News, views, and coverage of important topics and discussions from oncology conferences and events.
[widgetkit id="2" name="CC Highlights"]Results from the phase 3 SOLO1 trial demonstrate a substantial, unprecedented improvement in progression-free survival for olaparib versus placebo.
This combination of antiangiogenic and immune checkpoint blockade has clinical activity in women with recurrent ovarian cancer.
Results from the KEYNOTE-100 study show that expression of PD-L1 and inflamed T-cell–associated genes are associated with clinical response in advanced, recurrent ovarian cancer.
Durvalumab/PLD combination shows promising efficacy and a tolerable safety profile in women with platinum-resistant ovarian cancer.
Early intervention and supportive care for gastrointestinal and hepatic toxicities should be considered for patients receiving PARP inhibitors.
Analysis of high-grade serous ovarian cancers suggests that BRCA1/2-driven cancers have a more favorable mode of relapse than sporadic cancers.
Results suggest that the combination of durvalumab and olaparib was well-tolerated and had clinical activity in heavily pretreated, BRCA-wildtype ovarian cancer patients.
Olaparib maintenance may prolong progression-free survival in patients, regardless of the number of previous platinum-based chemotherapies.
Similar to the capsule formulation, olaparib tablets have no cumulative toxicity, few late-onset adverse events, and a low rate of treatment discontinuation.
Progression-free survival associated with rucaparib is not affected by the number of prior chemotherapy regimens.